Data as of Dec 04
| +0.09 / +3.90%|
Atossa Genetics, Inc. is a healthcare company that is focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer and through the research, development and ultimate commercialization of treatments for pre-cancerous lesions. The company has licensed the rights to develop, exploit and market the U.S. Food and Drug Administration approved Mammary Aspirate Cytology Specimen Test (MASCT) System. The company offers two diagnostic tests: ForeCYTE and ArgusCYTE. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offer two additional diagnostics tests: FullCYTE and NextCYTE. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. The company was founded by Steven C. Quay in December 2008 and is headquartered in Seattle, WA.
|Steven C. Quay||Chairman, President & Chief Executive Officer|
|Peter J. Carbonaro||Senior Vice President-Operations|
|Kyle Guse||CFO, Secretary & General Counsel|
|Shu-Chih Chen||Director & Chief Scientific Officer|
|Michael H. Kalnoski||Medical Director|